Olympus America

Press Center

New EMIT® II Plus Amphetamines and Ecstasy in Olympus Cartridges


Orlando, FL, July 26, 2005 - Olympus has announced the availability of two new EMIT® II Plus assays: Amphetamines (OSR9C229) and Ecstasy (OSR9X229). The assays expand the Drugs of Abuse (DOA) testing capabilities of the entire Olympus AU® chemistry-immuno analyzer system platform, including the AU400/400e®, AU600®, AU640/640e®, AU2700® and AU5400® chemistry-immuno analyzers. The EMIT II Plus Amphetamines and Ecstasy assays come in a liquid, ready-to-use format with 30-day on-board stability and are OSR bar-coded for convenient reagent management. Specific calibrator cutoffs are provided in accordance with proposed SAMHSA guidelines. The EMIT family of assays is widely recognized for excellence in drug diagnostic testing.

The EMIT II Plus Amphetamines assay is a homogeneous enzyme immunoassay with cutoff levels at 300 ng/mL, 500 ng/mL or 1000 ng/mL. The new Amphetamine antibody, d-meth and d-amph equivalent, enables greater separation, improved low-end sensitivity and a greater assay range (150-2000 ng/mL). The assay is intended for the qualitative or semi-quantitative analysis of amphetamines in human urine.

The EMIT II Plus Ecstasy assay is a homogeneous enzyme immunoassay with cutoff levels at 300 ng/mL or 500 ng/mL. The assay is intended for the qualitative or semi-quantitative analysis of methylenedioxymethamphetamine (MDMA) and closely related drugs (MDEA and MDA) in human urine. The Ecstasy assay can be used alone or in conjunction with the new Amphetamines assay.

For additional information about the two new Emit II Plus assays in Olympus cartridges, contact Carole Dauscher, Product Manager, Olympus Diagnostic Systems Group, at 1-800-223-0125 x5654 or email: carole.dauscher@olympus.com.

About Olympus Diagnostic Systems Group
Olympus Diagnostic Systems Group provides innovative solutions that meet the high productivity demands of hospitals, integrated healthcare delivery networks, reference labs, blood banks and pharmaceutical labs. Olympus offers the broadest standardized line of random access chemistry-immuno analyzers, along with lab automation systems, comprehensive patient safety systems, blood bank analyzers and reagents. Olympus solutions save laboratories time, enhance patient safety, maximize productivity, and deliver fast, reliable results.

About Olympus
Olympus is a precision technology leader, designing and delivering innovative solutions in healthcare and consumer electronics worldwide.

Olympus works collaboratively with its customers and its parent company, Tokyo-based Olympus Corporation, to leverage R&D investment in precision technology and manufacturing processes across diverse business lines. These include:

  • Gastrointestinal endoscopes, accessories, and minimally invasive surgical products;
  • Advanced clinical and research microscopes;
  • Lab automation systems, chemistry-immuno and blood bank analyzers and reagents; and
  • Digital and film cameras, and digital voice recorders.

In the U. S. and Canada, Olympus serves healthcare, scientific and commercial laboratory markets with integrated product solutions and financial, educational and consulting services that help customers efficiently, reliably, safely, and easily achieve superior results. Olympus is the leader in gastrointestinal endoscopy and clinical and educational microscopes. The company's market-leading consumer electronics business spans North and South America. For more information, visit www.olympusamerica.com.